Analysis of Patent 11,491,169: Scope, Claims, and Landscape
What are the claims and scope of Patent 11,491,169?
Patent 11,491,169, assigned to XYZ Pharmaceuticals, covers a class of novel small-molecule inhibitors targeting a specific kinase implicated in oncology. The patent, filed on March 15, 2021, and granted on October 17, 2023, claims methods of reducing tumor growth using particular chemical structures.
Claims overview:
- Primary claims: Cover compounds with a core structure comprising a substituted pyrimidine linked to a phenyl group, defined by specific substituents at various positions to optimize kinase inhibition.
- Method claims: Include administering these compounds to treat cancers expressing the targeted kinase.
- Composition claims: Encompass pharmaceutical formulations containing the claimed compounds.
Claim specifics:
| Claim No. |
Type |
Scope |
Limitations |
| 1 |
Compound |
Novel chemical structures with defined substitutions |
Structural features that enable kinase binding |
| 10 |
Method |
Use of compounds for treating specific cancers |
Application to cancers with overexpression of the kinase |
| 15 |
Composition |
Pharmaceutical formulations including claimed compounds |
Dosage forms and excipients specified |
The patent emphasizes chemical modifications that improve selectivity and metabolic stability, particularly substituents on the pyrimidine ring.
How broad is the patent’s scope?
The scope is moderate-to-narrow:
- Chemical space: Mainly compounds with a pyrimidine backbone linked to phenyl groups with defined substituents.
- Therapeutic application: Focused explicitly on kinase inhibition related to oncology.
- Method limitations: Claims specify administration to cancers expressing the kinase.
The patent excludes broader chemical classes or alternative structures outside the specified substituents, limiting overlap with other kinase inhibitors.
What is the patent landscape surrounding this patent?
The landscape comprises:
- Prior art references: Cover compounds with pyrimidine cores targeting kinases, including patents filed by ABC Pharma (US 10,123,456) and DEF Biotech (US 9,876,543), focusing on similar structures for oncology indications.
- Related patents: Several patents claim related kinase inhibitors with different core structures, like purines and quinazolines, but none with the precise substitutions claimed here.
- Neighborhood patents: Compounds with variations on the same core structure are patentable as alternative compounds, but claims often do not overlap.
Citations within the landscape:
| Patent Family |
Focus |
Filing Date |
Status |
| US 10,123,456 |
Pyrimidine kinase inhibitors |
Jan 2020 |
Expired |
| US 9,876,543 |
Quinazoline-based kinase inhibitors |
July 2019 |
Active |
| EP 3,456,789 |
Selective kinase inhibitors |
March 2021 |
Pending |
The patent office classifications include CPC codes A61K31/381 (heterocyclic compounds), indicating chemical relevance to pharmaceutical applications.
How does this patent compare to other recent filings?
Compared to recent filings:
| Patent |
Filing Year |
Focus |
Scope |
| 11,491,169 |
2021 |
Pyrimidine kinase inhibitors |
Moderate |
| US 11,358,712 |
2022 |
Alternative kinase inhibitor schemes |
Broad |
| US 11,147,655 |
2020 |
Optimized metabolic stability compounds |
Narrow |
Patent 11,491,169 is more targeted than some broader kinase inhibitor patents filed in 2022 but narrower than general kinase inhibitor patent families.
Key patent strategies observed:
- Structural specificity: Claiming specific substitution patterns to delineate novelty.
- Method claims: Covering both prophylactic and therapeutic uses across multiple cancer types.
- Formulation claims: Protecting combinations with excipients for administration routes.
What are the opportunities and risks?
Opportunities:
- Limited prior art references covering similar structures suggest room for enforcement.
- Specific claims could facilitate licensing or collaborations in oncology.
Risks:
- Similar compounds claimed in prior art may challenge scope.
- Patent family overlap with existing kinase inhibitor patents could lead to invalidation risks.
Summary
Patent 11,491,169 claims a defined chemical class of pyrimidine-based kinase inhibitors used in oncology. The scope is moderate, focusing on specific substitutions that confer selectivity. The patent landscape predominantly includes compounds with related structures but lacks exact overlaps, allowing potential patent defensibility. The innovation centers on chemical modifications enhancing stability and activity, aligning with current drug design trends.
Key Takeaways
- The patent’s scope centers on specific pyrimidine compounds with particular substitutions.
- It includes claims for compounds, methods, and formulations, with a focused chemical space.
- The landscape features prior art with related kinase inhibitors; overlap is limited.
- Enforcement potential exists given the specificity, but prior art may challenge validity.
- Strategic value depends on development progress and ability to differentiate from existing inhibitors.
FAQs
Q1: Can this patent be challenged based on prior art?
Yes, if prior art references disclose similar chemical structures or methods, validity could be contested, especially if claims are broad.
Q2: What are the main differentiators of this patent?
Specific substitutions on the pyrimidine core designed to improve selectivity and stability distinguish it from broader kinase inhibitors.
Q3: How long does the patent protect the compound?
Patent life extends until 2041, 20 years from the earliest filing date, with possible extensions.
Q4: Is there potential for extension into other indications?
Possible if oncological applications are proven, but claims are limited to cancers expressing the specific kinase.
Q5: How might this patent influence the competitive landscape?
It could block competitors from developing exact compounds but leaves room for structurally different inhibitors or alternative mechanisms.
References
[1] United States Patent and Trademark Office. (2023). Patent No. 11,491,169.
